Multivariable analyses
| . | Cumulative incidence of relapse/progression . | RFS . | OS . | |||
|---|---|---|---|---|---|---|
| sHR (95% CI)* . | P . | HR (95% CI)† . | P . | HR (95% CI)† . | P . | |
| All patients‡ | ||||||
| ELN2017 genetic risk (adverse vs intermediate vs favorable) | 1.89 (1.43-2.51) | <.001 | 1.99 (1.51-2.62) | <.001 | 1.56 (1.28-1.90) | <.001 |
| Number of remission at HSCT (second vs first) | 3.09 (1.85-5.17) | <.001 | 2.84 (1.79-4.51) | <.001 | — | — |
| Age at HSCT | — | — | — | — | 1.03 (1.02-1.05) | <.001 |
| Pre-HSCT remission status (MRD+ vs MRD−) | 2.77 (1.77-4.33) | <.001 | 2.73 (1-76-4.24) | <.001 | — | — |
| HSCT in first CR/CRi§ | ||||||
| ELN2017 genetic risk (adverse vs intermediate vs favorable) | 2.28 (1.36-3.82) | .002 | 2.22 (1.55-3.17) | <.001 | 1.58 (1.26-1.98) | <.001 |
| Pre-HSCT remission status (MRD+ vs MRD−) | 2.05 (1.43-2.93) | <.001 | 2.37 (1.40-4.00) | .001 | — | — |
| Conditioning regimen (MAC vs HSCT/NMA) | — | — | — | — | 0.66 (0.53-0.82) | <.001 |
| HSCT in second CR/CRiǁ | ||||||
| ELN2017 genetic risk (adverse vs intermediate vs favorable) | — | — | 1.57 (1.00-2.46) | .05 | 1.59 (1.04-2.45) | .03 |
| Duration of first remission (≥ 1 y vs <1 y) | 0.31 (0.16-0.59) | <.001 | 0.18 (0.07-0.51) | .001 | — | — |
| Pre-HSCT remission status (MRD+ vs MRD−) | 2.86 (1.44-5.69) | .003 | 4.04 (1.68-9.72) | .002 | — | — |
| . | Cumulative incidence of relapse/progression . | RFS . | OS . | |||
|---|---|---|---|---|---|---|
| sHR (95% CI)* . | P . | HR (95% CI)† . | P . | HR (95% CI)† . | P . | |
| All patients‡ | ||||||
| ELN2017 genetic risk (adverse vs intermediate vs favorable) | 1.89 (1.43-2.51) | <.001 | 1.99 (1.51-2.62) | <.001 | 1.56 (1.28-1.90) | <.001 |
| Number of remission at HSCT (second vs first) | 3.09 (1.85-5.17) | <.001 | 2.84 (1.79-4.51) | <.001 | — | — |
| Age at HSCT | — | — | — | — | 1.03 (1.02-1.05) | <.001 |
| Pre-HSCT remission status (MRD+ vs MRD−) | 2.77 (1.77-4.33) | <.001 | 2.73 (1-76-4.24) | <.001 | — | — |
| HSCT in first CR/CRi§ | ||||||
| ELN2017 genetic risk (adverse vs intermediate vs favorable) | 2.28 (1.36-3.82) | .002 | 2.22 (1.55-3.17) | <.001 | 1.58 (1.26-1.98) | <.001 |
| Pre-HSCT remission status (MRD+ vs MRD−) | 2.05 (1.43-2.93) | <.001 | 2.37 (1.40-4.00) | .001 | — | — |
| Conditioning regimen (MAC vs HSCT/NMA) | — | — | — | — | 0.66 (0.53-0.82) | <.001 |
| HSCT in second CR/CRiǁ | ||||||
| ELN2017 genetic risk (adverse vs intermediate vs favorable) | — | — | 1.57 (1.00-2.46) | .05 | 1.59 (1.04-2.45) | .03 |
| Duration of first remission (≥ 1 y vs <1 y) | 0.31 (0.16-0.59) | <.001 | 0.18 (0.07-0.51) | .001 | — | — |
| Pre-HSCT remission status (MRD+ vs MRD−) | 2.86 (1.44-5.69) | .003 | 4.04 (1.68-9.72) | .002 | — | — |
CI, confidence interval.
sHR, substitute hazard ratio, indicates lower (higher) risk of relapse for the first category listed for the dichotomous variables or for the lower (higher) values of the continuous variables.
HR, hazard ratio, <1 (>1) indicate lower (higher) risk of death or relapse for the first category listed for the dichotomous variables. Variables considered in the models were those significant at α = 0.10 in univariate analyses.
Multivariable model for the whole patient cohort: For CIR end point, variables considered were patient sex, ELN2017 genetic risk group, conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), number of remissions at HSCT (second vs first), and age at HSCT. For RFS end point, variables considered were patient sex, ELN2017 genetic risk group, conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), number of remission at HSCT (second vs first), and age at HSCT. For OS end point, variables considered were disease origin (secondary or therapy-related vs de novo), ELN2017 genetic risk group, donor type (matched related vs matched unrelated vs mismatched unrelated), number of chemotherapy cycles before HSCT, conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), number of remission at HSCT (second vs first), and age at HSCT.
Multivariable model for patients who underwent HSCT in first CR/CRi: for the CIR end point, variables considered were patient sex, ELN2017 genetic risk group, conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), and age at HSCT. For the RFS end point, variables considered were disease origin (secondary or therapy-related vs de novo), ELN2017 genetic risk group, conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), and age at HSCT. For OS end point, variables considered were disease origin (secondary or therapy-related vs de novo), ELN2017 genetic risk group, number of chemotherapy cycles before HSCT, conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), and age at HSCT.
Multivariable model for patients who underwent HSCT in the second CR/CRi: for the CIR end point, variables considered were patient sex, ELN2017 genetic risk group, duration of first remission (>1 y vs <1 y), conditioning regimen (NMA/HSCT vs MAC), and pre-HSCT remission status (MRD+ vs MRD−). For the RFS end point, the variables were disease origin (secondary or therapy-related vs de novo), ELN2017 genetic risk group, duration of first remission (>1 y vs <1 y), conditioning regimen (NMA/HSCT vs MAC), pre-HSCT remission status (MRD+ vs MRD−), and age at HSCT. For OS end point, the variables were disease origin (secondary or therapy-related vs de novo), ELN2017 genetic risk group, conditioning regimen (NMA/HSCT vs MAC), and age at HSCT.